The present invention relates to an oral soft capsule formulation comprising: (1) a filling material comprising dutasteride and (2) a soft capsule film containing succinylated gelatin, a plasticizer, and a cross-linking inhibitor. The inventive soft capsule formulation can maintain superior drug dissolution stability, disintegration time and sealability of formulation, regardless of packaging and storage and storage conditions and thus can be effectively used in the treatment of benign prostatic hyperplasia, prostate cancer, and male pattern alopecia.
